PCO
MCID: PLY011
MIFTS: 58

Polycystic Ovary Syndrome (PCO)

Categories: Endocrine diseases, Rare diseases

Aliases & Classifications for Polycystic Ovary Syndrome

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 12 75 25 37 55 43 44 15 17 72
Polycystic Ovarian Syndrome 75 53 25 15 33
Polycystic Ovaries 12 29 55
Pcos 12 53 25
Polycystic Ovarian Disease 12 25
Stein-Leventhal Syndrome 12 25
Sclerocystic Ovaries 25 72
Multicystic Ovaries 12 25
Polycystic Ovary Syndrome, Susceptibility to 6
Sclerocystic Ovarian Degeneration 25
Sclerocystic Ovary Syndrome 25
Cystic Disease of Ovaries 25
Cystic Disease of Ovary 25
Stein-Leventhal Synd. 12
Polycystic Ovary 12
Pcod 25
Pco 25

Classifications:



External Ids:

Disease Ontology 12 DOID:11612
KEGG 37 H01739
ICD9CM 35 256.4
MeSH 44 D011085
NCIt 50 C26862
SNOMED-CT 68 69878008
ICD10 33 E28.2
UMLS 72 C0032460 C1136382

Summaries for Polycystic Ovary Syndrome

Genetics Home Reference : 25 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems. Most women with polycystic ovary syndrome produce excess male sex hormones (androgens), a condition called hyperandrogenism. Having too much of these hormones typically leads to excessive body hair growth (hirsutism), acne, and male pattern baldness. Hyperandrogenism and abnormal levels of other sex hormones prevent normal release of egg cells from the ovaries (ovulation) and regular menstrual periods, leading to difficulty conceiving a child (subfertility) or a complete inability to conceive (infertility). For those who achieve pregnancy, there is an increased risk of complications and pregnancy loss. Due to irregular and infrequent menstruation and hormone abnormalities, affected women have an increased risk of cancer of the uterine lining (endometrial cancer). In polycystic ovary syndrome, multiple cysts in each ovary can be seen with medical imaging. These cysts are small, immature ovarian follicles. Normally, ovarian follicles contain egg cells, which are released during ovulation. In polycystic ovary syndrome, abnormal hormone levels prevent follicles from growing and maturing to release egg cells. Instead, these immature follicles accumulate in the ovaries. Affected women can have 12 or more of these follicles. The number of these follicles usually decreases with age. About half of all women with polycystic ovary syndrome are overweight or obese and are at increased risk of a fatty liver. Additionally, many women with polycystic ovary syndrome have elevated levels of insulin, which is a hormone that helps control blood sugar levels. By age 40, about 10 percent of overweight women with polycystic ovary syndrome develop abnormally high blood sugar levels (type 2 diabetes), and up to 35 percent develop prediabetes (higher-than-normal blood sugar levels that do not reach the cutoff for diabetes). Obesity and increased insulin levels (hyperinsulinemia) further increase the production of androgens in polycystic ovary syndrome. Women with polycystic ovary syndrome are also at increased risk for developing metabolic syndrome, which is a group of conditions that include high blood pressure (hypertension), increased belly fat, high levels of unhealthy fats and low levels of healthy fats in the blood, and high blood sugar levels. About 20 percent of affected adults experience pauses in breathing during sleep (sleep apnea). Women with polycystic ovary syndrome are more likely to have mood disorders such as depression compared to the general population.

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to alopecia, androgenetic, 1 and cortisone reductase deficiency, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is ENSG00000230704 (), and among its related pathways/superpathways are Glucose / Energy Metabolism and HIF-1 signaling pathway. The drugs Levonorgestrel and Lamotrigine have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and heart, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

NIH Rare Diseases : 53 Polycystic ovarian syndrome (PCOS) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. Women with this condition typically have high levels of hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. The cause of PCOS is unknown, but probably involves a combination of genetic and environmental factors. Treatment for PCOS may involve birth control pills and medications for diabetes and infertility. Medicines called anti-androgens are also used to speed the growth of hair and clear acne.

MedlinePlus : 43 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity, or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

KEGG : 37
Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. Clinical manifestations include oligomenorrhea or amenorrhea, hirsutism, and frequently infertility. Clinical signs of PCOS include elevated luteinizing hormone (LH) and gonadotropin-releasing hormone (GnRH) levels, whereas follicle-stimulating hormone (FSH) levels are muted or unchanged. As a result of the increase in GnRH, stimulation of the ovarian theca cells, in turn, produces more androgens. Risk factors for PCOS in adults includes insulin resistance (IR), type 2 diabetes, obesity, and cardiovascular disease. PCOS can be described as an oligogenic disorder in which the interaction of a number of genetic and environmental factors determine the heterogeneous, clinical, and biochemical phenotype. Management of clinical manifestations of PCOS includes oral contraceptives for menstrual irregularities and hirsutism. Treatment options for infertility include clomiphene, laparoscopic ovarian drilling, gonadotropins, and assisted reproductive technology.

Wikipedia : 75 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 554)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 33.3 SHBG CYP21A2 CYP19A1
2 cortisone reductase deficiency 33.0 CYP21A2 CYP17A1 CYP11A1
3 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 33.0 INSR INS IGF1
4 hyperinsulinism 32.7 SHBG INSR INS IGF1
5 cytochrome p450 oxidoreductase deficiency 32.6 CYP21A2 CYP17A1
6 infertility 32.3 PRL GNRH1 GDF9 CYP19A1
7 gestational diabetes 32.3 SHBG INSR INS CAPN10
8 glucose intolerance 32.3 SHBG INSR INS IGF1
9 amenorrhea 32.2 SHBG PRL GNRH1
10 ovarian disease 32.2 SHBG PRL INS IGF1 GNRH1 GDF9
11 anovulation 32.2 SHBG PRL INS IGF1 GNRH1 CYP19A1
12 acanthosis nigricans 31.9 SHBG PRL INSR INS IGF1
13 androgenic alopecia 31.8 SHBG PRL CYP19A1
14 hyperprolactinemia 31.8 SHBG PRL IGF1 GNRH1
15 insulin-like growth factor i 31.6 SHBG PRL INSR INS IGF1
16 galactorrhea 31.5 PRL IGF1
17 estrogen excess 31.5 SHBG PRL CYP19A1
18 diabetes mellitus 31.4 SHBG INSR INS IGF1 CAPN10
19 body mass index quantitative trait locus 11 31.3 SHBG INSR INS IGF1 CYP21A2 CAPN10
20 hyperandrogenism 31.3 SHBG PRL INSR INS IGF1 GNRH1
21 acromegaly 31.2 PRL INS IGF1
22 hypogonadotropism 31.2 PRL GNRH1
23 fetal macrosomia 31.2 INSR INS IGF1
24 lipoid congenital adrenal hyperplasia 31.1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
25 precocious puberty 31.1 GNRH1 CYP21A2 CYP19A1
26 hyperglycemia 31.1 INSR INS IGF1
27 pituitary gland disease 31.1 PRL INS IGF1 GNRH1
28 diabetes mellitus, noninsulin-dependent 31.0 SHBG INSR INS IGF1 GAS5 CAPN10
29 aromatase deficiency 30.9 INS GNRH1 CYP19A1
30 hyperthyroidism 30.9 SHBG PRL INS
31 breast disease 30.8 SHBG PRL IGF1 CYP19A1
32 donohue syndrome 30.8 INSR INS IGF1
33 endometrial cancer 30.8 SHBG INS IGF1 GNRH1 GAS5 CYP19A1
34 central precocious puberty 30.7 IGF1 GNRH1
35 premature ovarian failure 1 30.7 SHBG PRL GNRH1 GDF9 CYP19A1 CYP11A1
36 empty sella syndrome 30.7 PRL IGF1 GNRH1
37 gynecomastia 30.7 SHBG PRL CYP19A1
38 chromophobe adenoma 30.7 PRL INS GNRH1
39 premenstrual tension 30.7 SHBG PRL GNRH1
40 overnutrition 30.6 SHBG INS IGF1
41 hypopituitarism 30.5 PRL INS IGF1 GNRH1
42 craniopharyngioma 30.5 PRL INS IGF1 GNRH1
43 transsexualism 30.4 CYP21A2 CYP19A1 CYP17A1
44 adrenal cortical adenoma 30.4 CYP21A2 CYP17A1 CYP11A1
45 conn's syndrome 30.3 PRL CYP21A2 CYP17A1 CYP11A1
46 luteoma 30.3 CYP21A2 CYP19A1
47 adrenal adenoma 30.2 CYP21A2 CYP17A1 CYP11A1
48 adrenal carcinoma 30.1 CYP21A2 CYP17A1 CYP11A1
49 gonadal disease 29.8 SHBG PRL INS IGF1 GNRH1 GDF9
50 breast cancer 27.7 SHBG PRL MSR1 INS IGF1 GNRH1

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 CAPN10 CYP11A1 CYP17A1 CYP19A1 FST GDF9
2 endocrine/exocrine gland MP:0005379 10.02 CAPN10 CYP11A1 CYP19A1 FST GDF9 GNRH1
3 adipose tissue MP:0005375 9.85 CAPN10 CYP17A1 CYP19A1 IGF1 INS INSR
4 liver/biliary system MP:0005370 9.7 CAPN10 CYP11A1 CYP19A1 GNRH1 INS INSR
5 renal/urinary system MP:0005367 9.43 CAPN10 CYP19A1 GNRH1 IGF1 INS INSR
6 reproductive system MP:0005389 9.32 CYP11A1 CYP17A1 CYP19A1 FST GDF9 GNRH1

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
2
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
5
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
6
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Alogliptin Approved Phase 4 850649-61-5 11450633
9
Citalopram Approved Phase 4 59729-33-8 2771
10
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
11
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
12
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
13
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
14
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
15
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
16
Tamoxifen Approved Phase 4 10540-29-1 2733526
17
Liraglutide Approved Phase 4 204656-20-2 44147092
18
Glucagon Approved Phase 4 16941-32-5
19
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Drospirenone Approved Phase 4 67392-87-4 68873
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
26
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
27
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
28
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
29
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
30
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
31
leucovorin Approved Phase 4 58-05-9 143 6006
32
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
33
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
34
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
35
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
36
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
37
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
38
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
39
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
40
Cobalamin Experimental Phase 4 13408-78-1 6857388
41 Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
42
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
43
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
44 Diuretics, Potassium Sparing Phase 4
45 Hemostatics Phase 4
46 carnitine Phase 4
47 Anticonvulsants Phase 4
48 calcium channel blockers Phase 4
49 GABA Agents Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 753)
# Name Status NCT ID Phase Drugs
1 Endometrial Scratching at Time of Laproscopic Ovarian Drilling in Women With Anovulatory Infertility Due to Polycystic Ovarian Syndrome (PCOS): Randomized Controlled Trial. Unknown status NCT02140398 Phase 4
2 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
3 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
4 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
5 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
6 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
7 Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome. Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
8 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
9 The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
10 Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study Unknown status NCT02215135 Phase 4 Corifollitropin alfa
11 Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
12 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
13 A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
14 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
15 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
16 Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
17 Hormone Profiles in Adults Treated With Valproate vs. Lamotrigine Monotherapy for Newly Diagnosed Epilepsy: A Prospective Randomised Study Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
18 Prospective Randomized Trial on GnRH Agonist Triggering Versus hCG Triggering in IVF Stimulation in PCOS Patients Unknown status NCT01683513 Phase 4 GnRh agonist +1500E hCG
19 Adding L-carnitine in Clomiphene Resistant Pco Improves the Quality of Ovulation and the Pregnancy Outcome,a Randomized Clinical Trial Unknown status NCT01665547 Phase 4 l-carnitine
20 Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages Unknown status NCT01718340 Phase 4 Metformin
21 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
22 Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial Unknown status NCT02703649 Phase 4 Letrozole
23 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
24 Phytoestrogens as an Alternative to Estradiol in Reversing the Antiestrogenic Effect of Clomid on Endometrium in Ovulation Induction in Cases of Polycystic Ovarian Syndrome Completed NCT02352597 Phase 4 phytoestrogen;estradiol valerate;clomiphene citrate
25 Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes Completed NCT01504321 Phase 4 Moxonidine;Placebo
26 Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
27 Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome Completed NCT01899430 Phase 4 liraglutide;metformin
28 Effects of Structured Exercise Program Versus Hypocaloric Hyperproteic Diet on the Reproductive Function in Obese Anovulatory Infertile Patients With Polycystic Ovary Syndrome: a 24-Week Prospective Study. Completed NCT00473538 Phase 4
29 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Completed NCT02483299 Phase 4 Metformin;Glucophage tablets and Victoza
30 Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS Completed NCT02683226 Phase 4 Vipdomet;Incresync
31 Therapeutic Effect of Vitamin D3 Supplementation to Clomiphene Citrate Resistant Polycystic Ovary Syndrome Women Completed NCT04010942 Phase 4 Vit D;Metformin;Clomiphene
32 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
33 The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
34 Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
35 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
36 Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity Completed NCT02909933 Phase 4 liraglutide;metformin and liraglutide
37 Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial Completed NCT01279512 Phase 4 Metformin;Acarbose
38 A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis. Completed NCT02073929 Phase 4 Liraglutide for 26 weeks;placebo
39 Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom før og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance) Completed NCT01892254 Phase 4 Metformin;Placebo
40 A Clinical Trial to Measure the Effect of DHA-enriched Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat Content in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
41 The Effect of Metformin on Serum Insulin, Androgens and AMH in PCOS Patients Completed NCT02568488 Phase 4 Metformin
42 The Effect of Cipralex in Polycystic Ovary Syndrome Completed NCT01961180 Phase 4 Cipralex;Placebo
43 A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR® Versus FOLLISTIM® in Polycystic Ovarian Syndrome (PCOS) Patients Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
44 The Effects of Oral Isotretinoin in Women With Acne and Polycystic Ovary Syndrome Completed NCT02855138 Phase 4 oral isotretinoin
45 Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
46 Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
47 Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome Completed NCT00478504 Phase 4 Letrozole;Clomifene citrate
48 Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial Completed NCT01896492 Phase 4 NAC
49 Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
50 To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS) Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo

Search NIH Clinical Center for Polycystic Ovary Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ethynodiol diacetate
Mestranol
Metformin
Norelgestromin
Norgestrel
Urofollitropin

Cochrane evidence based reviews: polycystic ovary syndrome

Genetic Tests for Polycystic Ovary Syndrome

Genetic tests related to Polycystic Ovary Syndrome:

# Genetic test Affiliating Genes
1 Polycystic Ovaries 29

Anatomical Context for Polycystic Ovary Syndrome

MalaCards organs/tissues related to Polycystic Ovary Syndrome:

41
Ovary, Liver, Heart, Endothelial, Testes, Pituitary, Skin

Publications for Polycystic Ovary Syndrome

Articles related to Polycystic Ovary Syndrome:

(show top 50) (show all 13692)
# Title Authors PMID Year
1
Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. 9 38 71
14602801 2003
2
Comment: CAPN10 alleles are associated with polycystic ovary syndrome. 9 38 71
12161543 2002
3
Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). 38 17
31029778 2019
4
The role of MiRNA in polycystic ovary syndrome (PCOS). 38 17
31054362 2019
5
Association of Kiss1 and GPR54 Gene Polymorphisms with Polycystic Ovary Syndrome among Sri Lankan Women. 38 17
30993114 2019
6
Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. 71
14574648 2003
7
Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. 71
11481585 2001
8
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. 71
11017071 2000
9
Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome. 9 38
20514429 2010
10
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome. 9 38
19376510 2010
11
No association of the G972S polymorphism of the insulin receptor substrate-1 gene with polycystic ovary syndrome in lean PCOS women with biochemical hyperandrogenemia. 9 38
20012307 2010
12
C-reactive protein and homocysteine levels are associated with abnormal heart rate recovery in women with polycystic ovary syndrome. 9 38
19362308 2010
13
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 9 38
19342032 2010
14
CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. 9 38
19324338 2010
15
Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. 9 38
20185515 2010
16
Insulin resistance and overweight-obese women with polycystic ovary syndrome. 9 38
19903118 2010
17
Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome. 9 38
20103703 2010
18
The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. 9 38
19171332 2010
19
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome. 9 38
20096985 2010
20
Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome. 9 38
20093255 2010
21
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. 9 38
19489873 2010
22
High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. 9 38
20080859 2010
23
Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). 9 38
20008886 2010
24
Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. 9 38
19171337 2010
25
[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]. 9 38
20450755 2010
26
Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. 9 38
20148738 2010
27
Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. 9 38
20089616 2010
28
Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. 9 38
19926323 2010
29
Decreased adiponectin levels in polycystic ovary syndrome, independent of body mass index. 9 38
19929617 2010
30
Serum retinol-binding protein 4 levels in nonobese women with polycystic ovary syndrome. 9 38
19028383 2010
31
Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. 9 38
19892338 2010
32
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. 9 38
19111298 2010
33
Unilateral ovarian enlargement in adolescents with polycystic ovary syndrome: a variant of bilateral disease. 9 38
20432811 2010
34
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance]. 9 38
20367923 2010
35
Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS). 9 38
19438903 2010
36
Adiponectin and resistin concentrations after glucose load in adolescents with polycystic ovary syndrome. 9 38
19639497 2010
37
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. 9 38
19019358 2010
38
Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women. 9 38
19938957 2009
39
Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. 9 38
19596311 2009
40
Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. 9 38
19905998 2009
41
Effects of polymorphisms of the sex hormone-binding globulin (SHBG) gene on free estradiol and bone mineral density. 9 38
19679209 2009
42
[Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation]. 9 38
20209851 2009
43
Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). 9 38
19389110 2009
44
The relationship between follistatin and chronic low-grade inflammation in women with polycystic ovary syndrome. 9 38
19591997 2009
45
Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. 9 38
19700156 2009
46
Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. 9 38
20015405 2009
47
[The activity of platelet activating factor acetylhydrolase and its metabolic profile in patients with polycystic ovary syndrome]. 9 38
20067121 2009
48
Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. 9 38
19704410 2009
49
Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. 9 38
19654109 2009
50
Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. 9 38
19713424 2009

Variations for Polycystic Ovary Syndrome

ClinVar genetic disease variations for Polycystic Ovary Syndrome:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CAPN10 NM_023083.4(CAPN10): c.471-187T> C single nucleotide variant risk factor rs2975760 2:241531163-241531163 2:240591746-240591746

Expression for Polycystic Ovary Syndrome

Search GEO for disease gene expression data for Polycystic Ovary Syndrome.

Pathways for Polycystic Ovary Syndrome

GO Terms for Polycystic Ovary Syndrome

Cellular components related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 PRL INS

Biological processes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 PRL INSR INS IGF1 GDF9
2 steroid metabolic process GO:0008202 9.72 CYP21A2 CYP17A1 CYP11A1
3 activation of protein kinase B activity GO:0032148 9.61 INSR INS IGF1
4 positive regulation of mitotic nuclear division GO:0045840 9.58 INSR INS IGF1
5 steroid biosynthetic process GO:0006694 9.56 CYP21A2 CYP19A1 CYP17A1 CYP11A1
6 positive regulation of glycolytic process GO:0045821 9.54 INSR INS IGF1
7 male sex determination GO:0030238 9.52 INSR GNRH1
8 amyloid-beta clearance GO:0097242 9.51 MSR1 INSR
9 positive regulation of glycogen biosynthetic process GO:0045725 9.5 INSR INS IGF1
10 neuron projection maintenance GO:1990535 9.48 INSR INS
11 positive regulation of respiratory burst GO:0060267 9.46 INSR INS
12 glucocorticoid biosynthetic process GO:0006704 9.33 CYP21A2 CYP17A1 CYP11A1
13 positive regulation of glucose import GO:0046326 9.26 INSR INS IGF1 CAPN10
14 ovulation cycle GO:0042698 9.19 GNRH1
15 sterol metabolic process GO:0016125 8.8 CYP21A2 CYP19A1 CYP11A1

Molecular functions related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.62 CYP21A2 CYP19A1 CYP17A1 CYP11A1
2 heme binding GO:0020037 9.56 CYP21A2 CYP19A1 CYP17A1 CYP11A1
3 hormone activity GO:0005179 9.46 PRL INS IGF1 GNRH1
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5 insulin-like growth factor receptor binding GO:0005159 8.8 INSR INS IGF1

Sources for Polycystic Ovary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....